Pancreatic Cancer Research

Clinical trialPhase 1Active not recruiting

First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer

A Phase 1, First in Human, Dose-Escalation Study of TORL-2-307-ADC in Participants With Advanced Cancer

Outcome
Ongoing
Phase
Phase 1
Status
Active not recruiting
Study type
Interventional
Start
2 February 2022
Expected end
15 February 2027
Enrollment
163 participants
Sites
12
Primary outcomes
Incidence and severity of adverse events and serious adverse events; Maximum Tolerated Dose (MTD); Recommended Phase 2 Dose (RP2D)
Sponsor type
Industry
Results posted
No
Last update
13 January 2026

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-2-307-ADC in patients with advanced cancer